24/7 Market News- BriaCell Reports Positive Phase II OS in Metastatic Breast Cancer

September 11, 2024

DENVER, Colo., Sep 11, 2024 (247marketnews.com)- BriaCell Therapeutics (Nasdaq: BCTX) reported positive overall survival data from its Phase 2 clinical study of Bria-IMT in combination with an immune check point inhibitor (CPI) in late-stage metastatic breast cancer.

The median overall survival of 15.6 months reported in BriaCell’s most recent patients (treated since 2022) is about double the 6.7-9.3 months for similar patients reported in the literature, and a significant improvement over BriaCell’s 13.4 months median overall survival previously reported in December 2023.

Sara A. Hurvitz, MD, Professor of Medicine, Fred Hutch Cancer Center and University of Washington and BriaCell medical advisory board member, commented, “Overall survival in patients with heavily pre-treated metastatic breast cancer is very poor.

“The BriaCell early data is quite encouraging from both efficacy and tolerability standpoints.”

Dr. William V. Williams, BriaCell’s President and CEO, followed, “We wanted to look at the Phase 2 data of those patients who most closely resemble the patients being treated in our ongoing phase 3 study and compare them to similar patients in the literature.

“The nearly two-fold overall survival benefit we are seeing with the Bria-IMT™ regimen, together with the similar previously reported approximate doubling of progression free survival, compared with literature controls, strongly support our belief that Bria-IMT™ could have a meaningful impact in the lives of heavily pre-treated metastatic breast cancer patients. We look forward to further clinical development of Bria-IMT™ with the goal of establishing it as a new standard of care for patients with metastatic breast cancer.”

Giuseppe Del Priore, MD, MPH, BriaCell’s Chief Medical Officer, added, “The Bria-IMT regimen is the only investigational drug we have seen to show these impressive survival numbers in heavily pre-treated metastatic breast cancer patients who have failed numerous prior treatments including immune check point inhibitors and antibody drug conjugates.

“These survival and clinical benefit data support BriaCell’s hypothesis of additive and/or synergistic effects of immune check point inhibitors with Bria-IMT™ and drive the ongoing pivotal study of our combination regimen in the treatment of metastatic breast cancer.”

Mobot alerted Briacell a minute after this morning’s announcement at $1.007 and 1.22M shares.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (BCTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.